Oramed to Present Results from its Phase 2a FDA Trial with ORMD-0801 at the 2014 Diabetes Summit on April 24, 2014

[at noodls] – JERUSALEM, March 3, 2014 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, … more

View todays social media effects on ORMP

View the latest stocks trending across Twitter. Click to view dashboard

See who Oramed is hiring next, click here to view